Sumit  Chanda, Ph.D.

Sumit Chanda, Ph.D.

Sanford Burnham Prebys Medical Discovery Institute

Director and Professor--Immunity and Pathogenesis Program

Expertise: virologistCoronaviruscovid 19SARS-CoV-2coronavirus treatmentAntiviral

Sumit Chanda, Ph.D., is a virologist at Sanford Burnham Prebys Medical Discovery Institute who is racing to find a treatment for COVID-19. 

His team is testing 13,000 compounds for effectiveness against SARS-CoV-2, leveraging a library created with the support of the Bill & Melinda Gates Foundation called the ReFRAME drug repurposing collection. All of the drugs tested are already approved by the FDA for another disease or have been tested extensively for human safety. 
Prior to the outbreak, Chanda’s lab was advancing broad-spectrum antivirals—medicines that would work against many viruses, not just one—that could protect us against a pandemic. 

No Clipping

No Research/Citations

Scientists identify promising immunotherapy combination for pediatric brain cancer

Scientists at Sanford Burnham Prebys have discovered that combining immunotherapy with a drug called tumor necrosis factor (TNF) eradicated a deadly type of pediatric brain tumor in mice. The discovery, published in Nature Neuroscience, is expected to lead to a clinical trial to test the benefits of the treatment in patients. The findings also hold implications for other cancers that do not respond to immunotherapy.
15-May-2020 12:50:48 PM EDT

Sanford Burnham Prebys to develop broad-spectrum antivirals with $10 million Department of Defense grant

Sanford Burnham Prebys Medical Discovery Institute is pleased to announce that Sumit Chanda, Ph.D., has received a $10.2 million, four-year grant from the Department of Defense to develop and advance broad-spectrum antivirals for respiratory diseases. The award aims to provide U.S. military forces and the nation with safe, effective and innovative therapies that combat multiple types of respiratory viruses.
08-May-2020 02:10:31 PM EDT

No Quotes

Media contact name : Susan Gammon

Media mobile No : +18586103808

Media email :